Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials. (PubMed, medRxiv) - Sep 25, 2026 - "Co-administration with delamanid and HIV co-infection resulted in a 37% increase and 20% decrease in clofazimine bioavailability, respectively. We estimated that clofazimine remained present in the body for longer than two years in over half of participants following 9 months of treatment. Follow-up studies are recommended to confirm these associations before adjusting clofazimine dose or clinical care decisions."
Journal • PK/PD data • Diabetes • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Tuberculosis
|
|
Allison N LaHood; Amanzhan Abubakirov; Anel Belgozhanova; Annum Aftab; Azka Ashraf; Belén P Solans; Bernard Ngara; Carole D Mitnick; Dante Vargas Vasquez; David Holtzman; Dinh Van Luong; Eunsol Yang; Fanny Garcia Velarde; Francis Varaine; Gustavo E Velásquez; Ha Tt Phan; Hanh T Nguyen; Helen McIlleron; Kanat Khazhidinov; Kwonjune J Seung; Loren Hans; Lorenzo Guglielmetti; Lubbe Wiesner; Maelenn Gouillou; Mahnoor S Arshad; Michael L Rich; Nelisiwe Ntuli; Pieter Van Brantegem; Rada Savic; Rina Swart; Sean Wasserman; Sergio Mucching Toscano; Sesomo Mohale; Stephane Mpinda
|